News Center

Remove all filters

Published September 1, 2021

מעורבות חולים ונציגיהם בפיתוח ואישור תרופות

Published August 30, 2021

Comparable efficacy & Similar Safety profile

כלל ההתוויות המאושרות^ של DARZALEX^® IV מאושרות עכשיו גם עבור DARZALEX^® SC.

Published June 21, 2021

Apalutamide and Overall Survival in Prostate Cancer

Published June 11, 2021

Hematology-GRIFFIN

Published June 4, 2021

Hidradenitis Suppurativa

Published June 4, 2021

Pemphigus Vulgaris

Published June 4, 2021

Atopic Dermatitis

Published June 3, 2021

Psoriasis

Published June 3, 2021

Alopecia Areata

Published June 3, 2021

Recommended Articles - UC

Gastroenterology

Published June 3, 2021

Recommended Articles - CD

Gastroenterology

Published June 3, 2021

חשיבות ודגשים לאבחון מוקדם של דלקת מפרקים פסוריאטית

Psoriasis & More

Published February 1, 2021

הטיפול הביולוגי לפסוריאזיס בהיריון

Published January 1, 2021

בין בריאות, אתיקה ומשפט

Published September 17, 2020

Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer

Published September 14, 2020

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Published September 11, 2020

Inferences About Drug Safety in Phase 3 Trials in Advanced Prostate Cancer

Published July 6, 2020

Practical Issues With Use of Edrafitinib in Urothelial Carcinom

Published June 9, 2020

ASCO 2020: SPARTAN Reveals Overall Survival Benefit of Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Published May 18, 2020

AUA 2020: Neoadjuvant Apalutamide + Prednisone With or Without Abiraterone/Prednisone Shows Promise in Facilitating Nerve-Sparing Radical Prostatectomy in High-Risk Prostate Cancer

Published May 16, 2020

AUA 2020: Neoadjuvant Apalutamide + Radical Prostatectomy Show Promise in Organ-Confined Prostate Cancer

Published May 5, 2020

Bladder Cancer Treatment Protocols

Published May 1, 2020

המלצות מעשיות לרופאי עור המשתמשים בטלמדיסין

Psoriasis & More

Published February 27, 2020

Time to Second Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide

Published February 24, 2020

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

Published February 22, 2020

Adjuvant FGFR3 Inhibition in Bladder Cancer

Published January 1, 2020

הגישה הטיפולית לביטויים ראומטיים של מחלת מעי דלקתית

Published November 1, 2019

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Published September 27, 2019

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Published September 19, 2019

Apalutamide Now Also Approved for Metastatic Prostate Cancer

Published September 2, 2019

FGFR Inhibitors in Bladder Cancer

Published August 24, 2019

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

Published July 25, 2019

High Response Rate With First Targeted Drug for Bladder Cancer

Published June 6, 2019

TITAN Solidifies Place for Apalutamide in Metastatic CSPC

Published April 15, 2019

FDA Approves First Targeted Therapy for Metastatic Bladder Cancer

Published April 12, 2019

FDA Okays First Targeted Drug for Metastatic Bladder Cancer

Published February 17, 2019

Erdafitinib in Urothelial Carcinoma

Published February 9, 2019

Erleada - comparative-assessment-prognostic-outcomes-between-first-generation-antiandrogens-and-novel-androgen

Published February 1, 2019

Managing Nonmetastatic Castration-resistant Prostate Cancer

Published January 8, 2019

Questions About Metastasis-Free Survival in Prostate Cancer

Published November 16, 2018

EU Green Lights Apalutamide for Nonmetastatic CRPC

Published September 19, 2018

New Data on QoL With Apalutamide in Prostate Cancer

Published September 10, 2018

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Published March 27, 2018

Apalutamide in nmCRPC: QOL as Good as ADT Alone